MX382977B - Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular. - Google Patents

Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular.

Info

Publication number
MX382977B
MX382977B MX2016005040A MX2016005040A MX382977B MX 382977 B MX382977 B MX 382977B MX 2016005040 A MX2016005040 A MX 2016005040A MX 2016005040 A MX2016005040 A MX 2016005040A MX 382977 B MX382977 B MX 382977B
Authority
MX
Mexico
Prior art keywords
methods
inflammation
diseases associated
eye diseases
vascular proliferation
Prior art date
Application number
MX2016005040A
Other languages
English (en)
Inventor
James Kelly Darren
Stapleton David
Original Assignee
Occurx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010905197A external-priority patent/AU2010905197A0/en
Application filed by Occurx Pty Ltd filed Critical Occurx Pty Ltd
Publication of MX382977B publication Critical patent/MX382977B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para el tratamiento de enfermedades oculares asociadas con la inflamación y / o la proliferación vascular en sujetos se dan a conocer. Los métodos incluyen la administración de cantidades terapéuticamente eficaces de un compuesto tranilast, en particular ácido (E) -2 - [[3 - (3-metoxi-4-propargiloxi) fenil)-1-oxo-2-propenil] amino] benzoico o ácido (E) -2 - [[3,4-bis (difluorometoxi) fenil)-1-oxo-2-propenil] amino] benzoico o sales o solvatos farmacéuticamente aceptables de los mismos.
MX2016005040A 2010-11-24 2011-11-10 Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular. MX382977B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010905197A AU2010905197A0 (en) 2010-11-24 Methods of treating eye diseases associated with inflammation and vascular proliferation
PCT/AU2011/001455 WO2012068612A1 (en) 2010-11-24 2011-11-10 Methods of treating eye diseases associated with inflammation and vascular proliferation

Publications (1)

Publication Number Publication Date
MX382977B true MX382977B (es) 2025-03-12

Family

ID=46145280

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005039A MX382978B (es) 2010-11-24 2011-11-10 Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular.
MX2016005040A MX382977B (es) 2010-11-24 2011-11-10 Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular.
MX2013005561A MX352517B (es) 2010-11-24 2011-11-10 Metodo para tratar enfermedades de los ojos asociadas con inflamacion o proliferacion vascular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016005039A MX382978B (es) 2010-11-24 2011-11-10 Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013005561A MX352517B (es) 2010-11-24 2011-11-10 Metodo para tratar enfermedades de los ojos asociadas con inflamacion o proliferacion vascular.

Country Status (21)

Country Link
US (5) US9839640B2 (es)
EP (2) EP2642989B1 (es)
JP (1) JP5942131B2 (es)
KR (1) KR101899613B1 (es)
CN (1) CN103228275B (es)
AU (1) AU2011334592C1 (es)
CA (1) CA2815390C (es)
DK (2) DK2642989T3 (es)
ES (2) ES2722723T3 (es)
HR (1) HRP20190561T1 (es)
HU (1) HUE042676T2 (es)
MX (3) MX382978B (es)
NZ (1) NZ609144A (es)
PL (1) PL2642989T3 (es)
PT (1) PT2642989T (es)
RS (1) RS58603B1 (es)
SG (1) SG189326A1 (es)
SI (1) SI2642989T1 (es)
TR (1) TR201904760T4 (es)
WO (1) WO2012068612A1 (es)
ZA (1) ZA201302638B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722723T3 (es) * 2010-11-24 2019-08-16 Occurx Pty Ltd Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular
AU2018215089C1 (en) 2017-02-03 2022-09-22 Certa Therapeutics Pty. Ltd. Anti-fibrotic compounds
CN110357789B (zh) * 2018-04-11 2022-09-30 华东理工大学 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
JP2023529845A (ja) * 2020-06-05 2023-07-12 オキュルクス プロプライエタリー リミテッド 眼の障害の治療のための化合物及び方法
US20240174598A1 (en) * 2021-03-17 2024-05-30 Occurx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof
US11905231B1 (en) * 2023-01-31 2024-02-20 Certa Therapeutics Pty Ltd Solid forms, salts and polymorphs of anti-fibrotic compounds
KR20250032989A (ko) * 2023-08-28 2025-03-07 가톨릭대학교 산학협력단 방사선 유발 염증성 질환 예방용 조성물 및 이의 용도
CN120174076A (zh) * 2023-12-19 2025-06-20 温州医科大学附属眼视光医院 基于上皮-间质转化和纤维化的视频显示终端相关干眼诊断性生物标志物及治疗药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09176003A (ja) * 1995-12-28 1997-07-08 Tsumura & Co 角膜治療剤
US6407139B1 (en) * 1996-02-15 2002-06-18 Kissei Pharmaceutical Co., Ltd. Neovascularization inhibitor
JPH09278653A (ja) 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
JPH10259129A (ja) * 1997-01-16 1998-09-29 Kissei Pharmaceut Co Ltd 血管新生阻害剤
AU739271B2 (en) 1997-02-14 2001-10-11 Kissei Pharmaceutical Co. Ltd. Agents inhibiting progress of pterygium and postoperative recurrence of the same
JPH10330254A (ja) * 1997-04-01 1998-12-15 Kissei Pharmaceut Co Ltd 翼状片の進行および術後の再発抑制剤
US20070254055A1 (en) 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
WO2006073126A1 (ja) 2005-01-06 2006-07-13 Kissei Pharmaceutical Co., Ltd. 慢性移植片対宿主症におけるドライアイの予防および治療剤
SI2035369T1 (sl) * 2006-07-05 2014-11-28 Fibrotech Therapeutics Pty Ltd Terapevtske spojine
WO2008131481A1 (en) * 2007-04-26 2008-11-06 Fibrotech Therapeutics Pty Ltd Treatment of mesangioproliferative diseases
CN101730467A (zh) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 神经病性疼痛的治疗
WO2009079692A1 (en) 2007-12-21 2009-07-02 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
WO2010144959A1 (en) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
EP2947073B1 (en) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
ES2722723T3 (es) 2010-11-24 2019-08-16 Occurx Pty Ltd Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular

Also Published As

Publication number Publication date
US10786510B2 (en) 2020-09-29
MX382978B (es) 2025-03-12
MX2013005561A (es) 2014-11-10
US20130310386A1 (en) 2013-11-21
KR101899613B1 (ko) 2018-09-17
US10695353B2 (en) 2020-06-30
EP3485883B1 (en) 2020-08-26
PL2642989T3 (pl) 2019-07-31
JP5942131B2 (ja) 2016-06-29
CN103228275A (zh) 2013-07-31
DK2642989T3 (en) 2019-04-15
ES2829620T3 (es) 2021-06-01
PT2642989T (pt) 2019-04-23
SI2642989T1 (sl) 2019-07-31
EP2642989A1 (en) 2013-10-02
CA2815390A1 (en) 2012-05-31
AU2011334592A1 (en) 2013-05-02
HRP20190561T1 (hr) 2019-06-14
RS58603B1 (sr) 2019-05-31
US9839640B2 (en) 2017-12-12
ZA201302638B (en) 2023-07-26
EP2642989A4 (en) 2014-09-24
HUE042676T2 (hu) 2019-07-29
US20180117049A1 (en) 2018-05-03
KR20140012032A (ko) 2014-01-29
CN103228275B (zh) 2016-08-10
US20210244741A1 (en) 2021-08-12
EP3485883A1 (en) 2019-05-22
MX352517B (es) 2017-04-06
NZ609144A (en) 2014-08-29
AU2011334592C1 (en) 2015-04-02
CA2815390C (en) 2021-07-13
AU2011334592B2 (en) 2014-10-23
JP2014502267A (ja) 2014-01-30
WO2012068612A1 (en) 2012-05-31
TR201904760T4 (tr) 2019-04-22
DK3485883T3 (da) 2020-10-12
US11583535B2 (en) 2023-02-21
US20180117051A1 (en) 2018-05-03
ES2722723T3 (es) 2019-08-16
US20180117050A1 (en) 2018-05-03
SG189326A1 (en) 2013-05-31
EP2642989B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
MX382977B (es) Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular.
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
MX2009010407A (es) Derivados fluorados de deferiprona.
MX369385B (es) Productos para cicatrizar heridas tisulares.
PH12014500386A1 (en) Combination treatment for hepatitis c
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
IN2015DN04175A (es)
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
HK1198812A1 (en) Treatment of rhinitis
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX346186B (es) Inhibidores de proteina cinasas.
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
IN2014DN05869A (es)
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
CA2794655A1 (en) Method for treating schizophrenia and related diseases
MX2013006564A (es) Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico.
GEP20156332B (en) Pyrazoles as crth2 antagonists
WO2010039187A3 (en) Fused diimidazodiazepine compounds and methods of use and manufacture thereof
MX2013006031A (es) Formulacion liposomal de dalcetrapib.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions